Viridian Therapeutics announced that the Company has appointed Scott Myers as President and Chief Executive Officer, and a member of the Board of Directors, effective today February 6, 2023. Myers has more than 30 years of biopharmaceutical and medical technology experience, and has held global executive leadership and director roles at numerous commercial- and development-stage biopharmaceutical companies. He succeeds Jonathan Violin, Ph.D. who has led Viridian since its inception in 2020. Myers most recently served as the CEO and Director of AMAG Pharmaceuticals, where he led its turnaround and strategic sale to Covis Pharma.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on VRDN:
- Viridian Appoints Scott Myers as President and Chief Executive Officer
- Viridian Therapeutics to participate in a conference call with JMP Securities
- Viridian Therapeutics removed from tactical outperform list at Evercore ISI
- Viridian Therapeutics price target raised to $46 from $40 at B. Riley
- Viridian Announces Positive Data from Ongoing Phase 1/2 Trial Evaluating Low Dose VRDN-001 in Patients with Thyroid Eye Disease (TED)